- Home
- FEMY vs GOVX Comparison
FEMY vs GOVX Comparison
Compare FEMY & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- GOVX
- Stock Information
- Founded
- FEMY 2004
- GOVX 2001
- Country
- FEMY United States
- GOVX United States
- Employees
- FEMY N/A
- GOVX N/A
- Industry
- FEMY Medical/Dental Instruments
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- GOVX Health Care
- Exchange
- FEMY Nasdaq
- GOVX Nasdaq
- Market Cap
- FEMY 27.2M
- GOVX 23.8M
- IPO Year
- FEMY 2021
- GOVX N/A
- Fundamental
- Price
- FEMY $1.09
- GOVX $2.29
- Analyst Decision
- FEMY Strong Buy
- GOVX Strong Buy
- Analyst Count
- FEMY 3
- GOVX 5
- Target Price
- FEMY $10.00
- GOVX $14.20
- AVG Volume (30 Days)
- FEMY 185.8K
- GOVX 721.3K
- Earning Date
- FEMY 11-12-2024
- GOVX 11-12-2024
- Dividend Yield
- FEMY N/A
- GOVX N/A
- EPS Growth
- FEMY N/A
- GOVX N/A
- EPS
- FEMY N/A
- GOVX N/A
- Revenue
- FEMY $1,260,643.00
- GOVX $3,090,161.00
- Revenue This Year
- FEMY $157.75
- GOVX N/A
- Revenue Next Year
- FEMY $254.07
- GOVX $150.51
- P/E Ratio
- FEMY N/A
- GOVX N/A
- Revenue Growth
- FEMY 15.33
- GOVX N/A
- 52 Week Low
- FEMY $0.73
- GOVX $1.09
- 52 Week High
- FEMY $2.40
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- FEMY 46.31
- GOVX 45.52
- Support Level
- FEMY $1.05
- GOVX $2.17
- Resistance Level
- FEMY $1.24
- GOVX $2.47
- Average True Range (ATR)
- FEMY 0.08
- GOVX 0.18
- MACD
- FEMY -0.00
- GOVX -0.03
- Stochastic Oscillator
- FEMY 16.00
- GOVX 23.53
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.